Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 287Specimen Handling 285pembrolizumab 258Cyclophosphamide 237Radiotherapy 233Nivolumab 187Cisplatin 174Biopsy 170Carboplatin 155Radiosurgery 142fludarabine 131Blood Specimen Collection 130Surveys and Questionnaires 120Gemcitabine 120Paclitaxel 115venetoclax 114Standard of Care 112Dexamethasone 105Bevacizumab 98Radiation 97Rituximab 92Oxaliplatin 89Cytarabine 88Capecitabine 88Drug Therapy 86Ipilimumab 85Doxorubicin 83durvalumab 81atezolizumab 76fludarabine phosphate 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ibritumomab tiuxetan × 90 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡